---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022708"
form_type: "8-K/A"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2026-05-13T20:05:17+00:00"
generated_at: "2026-05-13T22:13:53.035571+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# iMDx signs specimen collection agreement with Quest for GraftAssureCore test

## Summary
- Entered Specimen Collection Agreement with Quest Diagnostics for services supporting GraftAssureCoreTM test.
- GraftAssureCore is a blood test measuring donor-derived cell-free DNA (dd-cfDNA) via PCR platform.
- Agreement covers specimen collection-related services to commercialize the test.
- No financial terms or duration of the agreement disclosed in the filing.

## SEC filing metadata
- accession: 0001493152-26-022708
- form_type: 8-K/A
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2026-05-13T20:05:17+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 1.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315226022708/0001493152-26-022708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315226022708/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022708
- JSON: https://secwatch.observer/filing/0001493152-26-022708.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.